Shanghai Shandon Pharmaceutical Technology

Shanghai Shandon Pharmaceutical Technology is a clinical-stage biotechnology company based in China that focuses on the development of innovative therapies for metabolic diseases. The company's primary research and development efforts are directed toward addressing high-prevalence conditions such as type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Their lead programs include oral small molecule GLP-1 receptor agonists designed to provide more convenient treatment options compared to traditional injectable therapies. By leveraging expertise in medicinal chemistry and metabolic pathways, Shandon Pharmaceutical aims to deliver next-generation treatments that improve patient compliance and clinical outcomes. The company is currently advancing multiple candidates through early-stage clinical trials in China.